Lysosometargeted drug combination induces multiple organelle dysfunctions and noncanonical death in pancreatic cancer cells.
Oncol Rep
; 47(2)2022 02.
Article
en En
| MEDLINE
| ID: mdl-34958115
ABSTRACT
Pancreatic cancer is one of the leading causes of cancerrelated mortality and has the lowest 5year survival rate. Therefore, novel strategies are urgently required to treat pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) cells rely on enhanced lysosomal function for survival and proliferation to facilitate the degradation of contents accumulated via autophagy and macropinocytosis. Previously, we have reported that the combination of epidermal growth factor receptor/HER2 inhibitor lapatinib and sphingosine analog fingolimod (FTY720) confers a significant cytostatic effect in lung cancer cells. In the present study, the combined effects of these drugs on PDAC cell lines, BxPC3, KP4, PANC1 and MIA PaCa2, were examined. It was observed that FTY720 enhanced the lapatinibinduced cytotoxic effect and caused noncanonical and lysosomedependent death in PDAC cells. Lapatinib and FTY720 induced lysosomal swelling and inhibited lysosomal acidification. Combination treatment with lapatinib and FTY720 increased lysosomal membrane permeability, induced mitochondrial depolarization, induced endoplasmic reticulum stress and disturbed intracellular calcium homeostasis. Additionally, the cytotoxic effect of lapatinib was enhanced by hydroxychloroquine or the CDK4/6 inhibitor abemaciclib, both of which induce lysosomal dysfunction. Collectively, these results indicated that the lysosometargeted drug combination induces multiple organelle dysfunction and exerts a marked cytotoxic effect in PDAC cells.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Pancreáticas
/
Carcinoma Ductal Pancreático
/
Clorhidrato de Fingolimod
/
Lapatinib
/
Lisosomas
Límite:
Humans
Idioma:
En
Revista:
Oncol Rep
Asunto de la revista:
NEOPLASIAS
Año:
2022
Tipo del documento:
Article
País de afiliación:
Japón